Australian Biotech Viralytics Breaks Out With Doubling Deal
This article was originally published in PharmAsia News
With one deal, Australia’s Viralytics doubles its market capitalization to $48 million from $24 million, which can bring its lead melanoma product through trials to commercialization.
You may also be interested in...
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal
Venture investors who saw the company through a failed IPO attempt receive long-awaited returns from a $425 million upfront payment.
Prima Shifts Focus To LAG-3 After Immutep Deal
The Australian immuno-therapeutics developer Prima BioMed has had a change of focus in recent months since buying Paris-based Immutep in late 2014. Prima’s lead product used to be its CVac cancer vaccine, but it has now shifted strategic priority to an LAG-3 immune checkpoint receptor that came with the acquisition.